Free Trial
NYSE:ATNM

Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Actinium Pharmaceuticals logo
$1.52 -0.03 (-1.94%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.53 +0.01 (+0.39%)
As of 07/11/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actinium Pharmaceuticals Stock (NYSE:ATNM)

Key Stats

Today's Range
$1.49
$1.57
50-Day Range
$1.35
$1.94
52-Week Range
$1.03
$8.64
Volume
203,660 shs
Average Volume
524,358 shs
Market Capitalization
$47.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Moderate Buy

Company Overview

Actinium Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ATNM MarketRank™: 

Actinium Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 645th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Actinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Actinium Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Actinium Pharmaceuticals is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Actinium Pharmaceuticals is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Actinium Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.54% of the float of Actinium Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Actinium Pharmaceuticals has recently decreased by 6.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Actinium Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Actinium Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.54% of the float of Actinium Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Actinium Pharmaceuticals has recently decreased by 6.99%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Actinium Pharmaceuticals has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Actinium Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    6 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.00% of the stock of Actinium Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

  • Read more about Actinium Pharmaceuticals' insider trading history.
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

ATNM Stock Analysis - Frequently Asked Questions

Actinium Pharmaceuticals' stock was trading at $1.26 at the beginning of the year. Since then, ATNM shares have increased by 20.6% and is now trading at $1.52.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) issued its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02.

Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Fitbit (FIT) and OHR Pharmaceutical (OHRP).

Company Calendar

Last Earnings
8/05/2024
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ATNM
Previous Symbol
NYSE:ATNM
CIK
1388320
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.00
Potential Upside/Downside
+163.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.82 million
Net Margins
N/A
Pretax Margin
-50,512.35%
Return on Equity
-100.85%
Return on Assets
-47.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.25
Quick Ratio
10.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
1.16

Miscellaneous

Outstanding Shares
31,196,000
Free Float
29,324,000
Market Cap
$47.42 million
Optionable
Optionable
Beta
-0.32
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NYSE:ATNM) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners